Europe's Pioneering Leaders Shaping the Future of Healthcare- Edition 2

February Issue 02 2024 Navigating Tomorrow How AI is Reshaping European Healthcare Catalysts for Change Healthcare Leadership Strategies in Europe Anders Kronborg CEO ResoTher Pharma

Change Makers W innovators who are shaping the future of healthcare across Europe. It's a privilege to share with you stories of innovation, resilience, and transformative leadership that are driving positive change in our healthcare landscape. elcome to the latest issue of Euro Health Leaders, where we take you on a journey celebrating the latest technologies to building collaboration among stakeholders, their initiatives are focused on improving patient outcomes and ensuring equitable access to healthcare services for all. For aspiring healthcare professionals, this edition serves as a guiding light, offering valuable insights into the qualities and strategies that define successful leadership in this dynamic field. As you flip through the pages of this magazine, you'll discover the remarkable achievements and bold visions of Europe's healthcare pioneers. Editor’s Note Europe's healthcare system is encountering significant challenges, from the impacts of ageing populations to the rising costs of innovations and the scarcity of skilled personnel. However, amidst these challenges, there's an exciting transformation underway towards a more sustainable, resilient, and citizen-centric healthcare model. At the forefront of this transformation are visionary leaders who are reshaping the way we approach healthcare. Let us celebrate the spirit of innovation and resilience driving Europe's healthcare transformation forward. Together, let's envision a future where healthcare knows no bounds, and every individual has access to the quality care they deserve. In this edition, 'Europe's Pioneering Leaders Shaping the Future of Healthcare', we explore the inspiring journeys of these remarkable individuals. From leveraging Have an enlightening read ahead! Managing Editor

Contents Profile 22 08 Hanns-Christian Mahler Strategic Leadership for Pa?ents Anders and the Planet The Visionary Navigator Articles 16 Navigating Tomorrow How AI is Reshaping European Healthcare 26 Catalysts for Change Healthcare Leadership Strategies in Europe

L E A D E R S EUR Health Editor-in-Chief Managing Editor Executive Editor Visualiser Art & Design Head Co-designer Art & Picture Editor Business Development Manager Emily Business Development Executives Marketing Manager Sales Executives Featuring Person Company Brief Technical Consultants Assistant Technical Head Technical Head Anders Kronborg CEO ResoTher Pharma resotherpharma.com Assistant Digital Marketing Manager Digital Marketing Manager SME-SMO Executives Constantin Schön CEO Silony Spine silonyspine.com Research Analyst Circulation Manager Hanns-Christian Mahler CEO ten23 health ten23.health sales@eurohealthleaders.com Contact Us: Insights Success Media and Technology Pvt. Ltd. Survey No.133/134, Brand Square, Office No. 512, Kunjir Chowk, Pimple Saudagar, Pune, Maharashtra 411027. Phone - India: 7410033802, 8956487823 Email: info@eurohealthleaders.com For Subscription: www.eurohealthleaders.com https://twitter.com/eurohealthleaders Insights Success Media Tech LLC 555 Metro Place North, Suite 100, Dublin, OH 43017, United States Phone - +1614-602-4132 Email: info@eurohealthleaders.com For Subscription: www.eurohealthleaders.com Jack Weinstein CEO Relief Therapeutics relieftherapeutics.com Jesús Martin-Garcia CEO GeNeuro geneuro.com Follow us on : www.facebook.com/eurohealthleaders/ We are also available on : Copyright © 2024 Insights Success Media and Technology Pvt. Ltd., All rights reserved. The content and images used in this magazine should not be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from Insights success. Reprint rights remain solely with Insights Success Media and Technology Pvt. Ltd. Euro Health Leaders is powered by Insights Success Media and Technology Pvt. Ltd.

‘ Anders The Visionary Navigator The idea of helping make product that can improve people's quality of life or even saving some is very appealing to me. ‘ ‘ ‘ Anders Kronborg CEO ResoTher Pharma

‘ T T who not only understands the intricacies of the industry but also possesses the visionary zeal to reshape its future. Epitomizing the very essence of transformative leadership in this dynamic environment, as an insightful leader. Europe's Pioneering Leaders Shaping the Future of Healthcare he vast and ever-changing field of healthcare demands leaders driven by a strong and undying motivation to serve the community. These leaders stand at the intersection of dedication and innovation. Within this arena of healthcare leadership emerges a figure Mr. Kronborg's legacy is woven with significant achievements. At LEO Pharma, he played a pivotal role in the implementation of a strategic vision unveiled in 2016. His strategic ability is further exemplified by his instrumental role in securing full funding for ResoTher Pharma's phase 2a study. In this edition, we dive into Mr. Kronborg's journey, exploring the layers of his leadership and the transformative impact he has had on ResoTher Pharma. Anders Kronborg emerges CEO ResoTher Pharma As the biotechnology company, Mr. Kronborg has become synonymous with novel strategies that propel both organizations and industries into the future. of , a dynamic His story is a blueprint for those who aspire to redefine the landscape of healthcare. A Journey from Finance to Pharma Leadership With an impressive career spanning over 25 years, Mr. Kronborg has donned various hats, serving as CEO, CFO, and COO across esteemed organizations. His current role at ResoTher Pharma, assumed in February 2023, marks the zenith of his illustrious journey. Prior to this, he lent his strategic acumen as the CFO/EVP at LEO Pharma from October 2015 to September 2022. His professional path extends across diverse sectors, including notable positions at Kinnevik Investment AB, Metro International, TV2 Denmark, Berlingske Media, DR, and the Ministry of Finance. Mr. Kronborg, an accomplished economist, graduated from Copenhagen University in 1989, setting the foundation for a diverse and impactful career. His early professional years unfolded in the Ministry of Finance, where he spent seven years sharpening his skills in various roles. In 2007, his trajectory took a new turn as he joined Kinnevik, a prominent Swedish investment company listed in Stockholm. From 2012 to 2015, Mr. Kronborg assumed the role of COO for the entire group, steering private companies toward public listings alongside other investors. Nestled in the heart of Copenhagen, Denmark, ResoTher Pharma is at the forefront of resolution therapy, with the most advanced asset in its biotech arsenal, RTP-026, targeting myocardial infarction and other cardiovascular diseases. ‘ The subsequent chapter (2015-2022) saw Mr. Kronborg as the CFO and interim CEO of LEO Pharma, a global pharmaceutical company specializing in skin diseases. Over seven years in this role, he coordinated several transactions involving assets in early stages as well as those ready for phases 1, 2, and 3. Mr. Kronborg concluded his tenure at LEO Pharma in the fall of 2022 with plans for retirement. team.‘ ‘ Reflecting on his unexpected venture into the pharmaceutical industry, Mr. Kronborg recalls, "After years in the Ministry of Finance, another decade in the Danish Media industry, and seven years working for a Swedish investment company, I was contacted by a headhunter – LEO Pharma was looking for a new CFO. So, my way into the Pharma Industry was random." I think inclusion comes through delega?on, and sharing all informa?on helps everybody be part of the In January 2023, a new chapter unfolded as Mr. Kronborg became fascinated by the ResoTher Pharma project. Taking charge as CEO on February 1, 2023, he steered the company through the completion of Phase 1 and secured funding for Phase 2a, anticipating the first patient dosed in Q1 2024.

‘ In reflecting on his transition to ResoTher Pharma, Mr. Kronborg remarks, "I liked the CEO and the Company and the ambitious strategy, knowing that I had to learn something completely new and very different from the rest of my career." He adds, "And the idea of helping make a product that can improve people's quality of life or even save some was very appealing to me." Mr. Kronborg joined the company, seeing the possibility of bringing an asset with the potential to be first and best in class into the next phase and closer to reaching the patients. patients—percutaneous coronary intervention (PCI). While effective, PCI poses risks, particularly post-ischemic tissue reperfusion inflammation. This inflammation, identified as a key prognostic factor in cardiovascular disease, is a pivotal point for the organization's intervention. ResoTher Pharma's lead candidate, RTP-026, a peptide- based compound, stands as an evidence to the company's commitment to innovative pro-resolving therapies. Developed in collaboration with Queen Mary University of London, RTP-026 has exhibited promising outcomes in phase 1 trials, curbing inflammation without compromising safety standards. Founding Visions Established in 2016, ResoTher Pharma is a privately held clinical-stage biotech company based in Denmark dedicated to advancing compounds that induce inflammatory resolution in cardiovascular diseases. The company's inception was fuelled by a vision to develop compounds capable of promoting pharmacological resolution in cardiovascular diseases, a mission that has garnered support from a group of influential Danish investors. The groundbreaking compound takes inspiration from Annexin A1, a human protein renowned for its anti- inflammatory properties. RTP-026, derived from Annexin A1, orchestrates a cascade of cellular events to resolve inflammation, activate tissue healing, and significantly reduce the impact of myocardial infarction. ResoTher Pharma's scientific pursuit extends beyond the laboratory, reflecting in its mission to improve patient outcomes in cardiovascular medicine. Despite resource constraints, RTP-026 has successfully navigated phase 1 trials, attaining both safety and efficacy. Founded by board member Jeppe Øvlesen and Thomas Jonassen, MD, the head of the Scientific Advisory Board, ResoTher Pharma boasts a foundation grounded in expertise and vision. Professor Mauro Perretti, the co- inventor of the company's lead compound, RTP-026, further adds to the depth of knowledge and commitment within the company, holding a stake as a shareholder. This initiative is not just a scientific venture; it serves as a beacon of hope for those affected by PCI-related hyperinflammation. Recently awarded a 2.5-million-euro grant from the European Innovation Council, ResoTher Pharma's RTP-026 attracts attention and validation from industry leaders, inspiring it towards revolutionary advancements in cardiovascular medicine. ‘ ‘ Reflecting on his decision to join ResoTher Pharma, Mr. Kronborg expresses, "What inspired me was a combination of the founders and the small and dynamic set-up of a small semi-virtual run BioTech company." This sentiment encapsulates the essence of ResoTher Pharma – a venture driven by visionary founders and propelled by the agility of a dynamic, small-scale biotech organization. ResoTher Pharma's scien?fic pursuit extends beyond the laboratory, reflec?ng in its mission to improve pa?ent outcomes in cardiovascular medicine. Commitment to Cardiovascular Care ‘ ResoTher Pharma emerges as a significant force in the field of cardiovascular care, dedicated to addressing the gaps in the current treatments for ST-segment elevation myocardial infarction (STEMI). This condition, impacting millions globally, necessitates innovative therapeutic interventions that ResoTher Pharma is poised to provide. STEMI, constituting a significant portion of acute coronary syndromes, is a precursor to severe heart damage and complications. ResoTher Pharma's focus lies in the aftermath of the preferred treatment for STEMI

Mr. Kronborg, the driving force behind ResoTher Pharma, emphasizes their research-centric approach. "Our focus centres on our Phase 2A lead asset, marking us as a research-centric biotech enterprise. We target major pharmaceutical players, seeking partners or interested parties for collaboration or acquisition of our pioneering product," he declares. ResoTher Pharma is not just a company; it's a research-focused entity striving to develop a groundbreaking drug that could redefine the landscape of cardiovascular care. strategy, remaining open to diverse solutions such as IPOs, partnerships, private placements, and grants. The key emphasis is on maintaining focus by not advancing too many assets simultaneously, a prudent approach to financial sustainability. Beyond financial strategies, Mr. Kronborg injects a profound commitment to diversity and inclusion into ResoTher Pharma's organizational culture. Despite being a small, virtual company, the team manages to meet every week. "I think inclusion comes through delegation, and sharing all information helps everybody be part of the team," notes Mr. Kronborg. Strategic Leadership ResoTher Pharma operates as a small virtual company steered by the guidance of Mr. Kronborg. In his role as CEO, he holds the responsibility of overseeing the company's strategic direction, financial management, and operational decisions. Charting ResoTher Pharma to Success A forward-thinking leader with a commitment to positive outcomes, Mr. Kronborg outlines his vision for ResoTher Pharma. He emphasizes the path forward, "Our first goal is to get solid phase 2a data – showing that the asset has the same impact in humans as we demonstrated in animals earlier this year." This underscores the importance of robust clinical evidence in validating the efficacy of ResoTher Pharma's asset. Mr. Kronborg's approach to leadership goes beyond strategy, embracing collaboration and a distinctive style marked by substantial delegation and a foundation of trust. This leadership ethos sets the tone for ResoTher Pharma's dynamic operations. A significant milestone in Mr. Kronborg's tenure has been the successful securing of funding for the Phase 2a trial, a feat accomplished in November 2023. This achievement not only underscores Mr. Kronborg's tactical skills but also positions ResoTher Pharma at the forefront of pharmaceutical advancement. In the next phase of his vision, Mr. Kronborg envisions taking the asset to phase 2b, considering avenues like partnering with a big pharma entity, a licensing agreement, or funding through an IPO. The guiding principle behind these choices is to select options that offer the highest likelihood of successfully bringing the product to market while ensuring a reasonable return for investors. Recent strides within the company include the deliberate recruitment of three individuals, a strategic move that mirrors ResoTher Pharma's proactive stance in preparation for the impending execution of the Phase 2a study. Work, Learning, and Purpose Drawing upon his wealth of experience, Mr. Kronborg shares valuable advice, saying, "If you can combine learning something new and working with something that is meaningful to you and have fun at the same time, then you should go for it." This piece of wisdom encapsulates the essence of a fulfilling and purpose-driven professional journey, where the convergence of learning, meaningful work, and enjoyment becomes the cornerstone for personal and career satisfaction. Navigating Challenges With the current market condition, securing funding stands as the biggest challenge for many organizations. However, with the promising potential of its asset, ResoTher has triumphed over this hurdle by successfully securing full funding for Phase 2a, a significant milestone achieved recently. This funding comes from a consortium of investors who have been steadfast supporters since the company's inception, coupled with the added support of an EIC grant. Acknowledging the pervasive struggle for funding within the biotech sector, ResoTher Pharma adopts a flexible

Naviga?ng Tomorrow AI Reshaping Healthcare is How European Healthcare A healthcare systems are increasingly turning to AI to improve patient outcomes, streamline processes, and address the challenges of an aging population and rising healthcare costs. From diagnosis and treatment to patient care and administrative tasks, AI is reshaping every aspect of healthcare delivery. rtificial intelligence (AI) is emerging as a transformative force in various industries, and healthcare is no exception. Across Europe, In this article, we'll explore the ways in which AI is revolutionizing European healthcare and how stakeholders can navigate this rapidly evolving landscape. One of AI's most notable contributions to European healthcare lies in the field of diagnosis and treatment. AI- powered diagnostic tools are enabling healthcare professionals to more accurately and efficiently identify diseases and conditions, leading to earlier interventions and better outcomes for patients. For example, machine learning algorithms can analyze medical images such as X-rays, MRIs, and CT scans to detect abnormalities and assist radiologists in making faster and more accurate diagnoses. Additionally, AI-based decision support systems are helping clinicians develop personalized treatment plans based on a patient's unique medical history, genetic makeup, and other relevant factors. 16 | February 2024 www.eurohealthleaders.com 17 | February 2024 www.eurohealthleaders.com

In addition to improving diagnostic accuracy, AI is also enhancing the delivery of healthcare services. Virtual health assistants powered by AI are revolutionizing the way patients access care by providing round-the-clock support for scheduling appointments, refilling prescriptions, and answering medical questions. These virtual assistants not only improve the patient experience by offering convenient and timely access to healthcare services but also ease the burden on healthcare providers by automating routine tasks and reducing administrative overhead. organizations must invest in infrastructure and training to support the integration of AI technologies into existing workflows and ensure that clinicians and staff are equipped with the necessary skills and knowledge to leverage these tools effectively. Conclusion Despite these challenges, the potential benefits of AI in European healthcare are vast. By effectively using the power of AI to improve diagnosis, treatment, patient care, and administrative processes, healthcare organizations can enhance the quality, efficiency, and accessibility of care for patients across the continent. However, realizing this potential will require collaboration and innovation among policymakers, healthcare providers, technology vendors, and other stakeholders to navigate the complexities of AI and ensure that it is deployed in a way that maximizes its benefits while minimizing risks. With careful planning and investment, AI has the potential to transform European healthcare and pave the way for a healthier future for all. Furthermore, AI is playing a crucial role in predictive analytics and population health management. By analyzing vast amounts of health data, including electronic health records, genomic information, and wearable device data, AI algorithms can identify patterns and trends that may indicate emerging health issues at the population level. This enables healthcare organizations to proactively intervene to prevent disease outbreaks, manage chronic conditions more effectively, and allocate resources more efficiently to where they are needed most. Another area where AI is making a significant impact is in drug discovery and development. Traditional methods of drug discovery are time-consuming, expensive, and often fail to yield viable candidates for new therapies. AI- powered algorithms, however, can scan through massive datasets of molecular structures, genetic information, and clinical trial data to identify promising drug targets and predict the efficacy and safety of potential treatments. This not only accelerates the drug development process but also increases the likelihood of success, ultimately bringing new therapies to market faster and at lower costs. - Natalie May Despite the promise of AI in transforming European healthcare, there are also challenges and considerations that stakeholders must navigate. One such challenge is the need to ensure the ethical and responsible use of AI technologies. As AI becomes increasingly integrated into healthcare decision-making processes, there are concerns about bias, privacy, and accountability. It is essential for healthcare organizations to implement robust governance frameworks and standards to address these issues and ensure that AI algorithms are transparent, fair, and trustworthy. Additionally, there are practical considerations related to the implementation and adoption of AI in healthcare settings. These include concerns about data interoperability, cybersecurity, and the impact on the workforce. Healthcare 18 | February 2024 www.eurohealthleaders.com

Europe's Pioneering Leaders Shaping the Future of Healthcare Hanns-Christian Mahl Strategic Leadership for Pa?ents and the Planet L leadership. His professional journey spans over two decades, marked by a commitment to excellence and a relentless pursuit of advancing healthcare solutions. As an adjunct faculty member and lecturer at prestigious universities such as Frankfurt and Basel, he not only leads in practice but also contributes to the academic growth of future industry leaders. eading the charge in the transformative landscape of healthcare, Hanns-Christian Mahler stands as a model of innovation, compassion, and strategic both perspectives were only half correct – the answer was usually more complex and would be ‘it depends.’ Many apparent ‘truths’ in the textbooks were anecdotal and lacked primary data. My aspira?on was (and remains) to learn and be curious, to challenge beliefs and explore areas of where innova?on is possible. With the raised curiosity, I started my first job in pharmaceutical industry. My aspiration was (and remains) to learn and be curious, to challenge beliefs and explore areas of where innovation is possible. During my first job, my father passed away – I was CMC project leader for an antibody at that time, which may eventually have helped him as therapy. His doctors “did not believe in novel biotech medicines”. At the core of Mahler’s leadership philosophy is a deep- seated dedication to sustainability and human-centric healthcare. As the CEO of ten23 health, he champions the cause of developing pharmaceutical solutions that not only cater to patients’ needs but also contribute positively to the well-being of people and the planet. His expertise spans a spectrum, including biotech and small molecule product development, regulatory affairs, and commercialization, aligning seamlessly with the evolving demands of the industry. Since then, I was very determined to develop and commercialize medicines and advance innovation and biotechnology, in order to make a positive impact on patients’, providing cure, remedy and/or providing improved quality of life. Could you share the vision and mission that drives the company forward in the pharmaceutical medicine space? What sets ten23 health apart in the industry, and how does the company contribute to positive impacts for people and the planet? Mahler’s impact extends beyond the boardroom, reflected in his prolific contributions to the field. With a remarkable publication record of over 120 manuscripts and co- inventorship of more than 50 patents, he exemplifies the spirit of a lifelong learner and disruptor. At ten23 health, our commitments are Patients, People, Planet. Our services span from developing, to manufacturing and testing of sterile medicines. Our customers can benefit from our team’s industrial and regulatory expertise and scientific excellence, as well as our agility and dedication. Our focus is the patient, always ensuring safety, providing innovations for treatment and improved convenience and compliance, an area where drug/device combination products (like the ones we can support to develop and manufacture) play a huge role. In our exclusive interview, Mahler shares valuable insights into his strategic vision, the significance of sustainability in pharmaceutical development, and his commitment to positive societal and environmental impact. Tell us about your journey in the pharmaceutical industry. What inspired you to become a leader in this field? Studying Pharmacy and doing my PhD, I noticed that some textbooks provided different responses to the same question, e.g. “solutions of which pH values can be injected.” This raised my curiosity, and I found out that “People” relates for example to ten23’s commitments related to fairness, justice, equity, diversity and inclusion, our support for the LGTBQ+ community, our focus on 22 | February 2024 www.eurohealthleaders.com

is a risk for the patient, and/or how the patient may further benefit. We consider it our responsibility as a CDMO to consult the customers for the benefit of their patients – whilst many experienced Customers and Pharmas of course have these perspectives themselves, some customers may not readily have that perspective, rather than focusing on the active ingredient and pharmacology. We are supporting various programs, where the patient or user is in the center: how to design the product (e.g., define the formulation, select primary packaging, select device and needle) to ensure the User can use this appropriately? How to dilute? Dose? Infuse? sustainable work and physical and mental health. And “Planet” relates to our commitments towards sustainability in everything we do. ten23 can uniquely support our customers in their development and commercialization of sterile medicines. And we want to lead in the way of “how” we operate, and with this, lead and disrupt traditional beliefs and concerns in the CDMO and Pharma sector. What do you envision as the key trends or changes in the future of healthcare, and how is ten23 health positioned to adapt to these shifts? Active ingredients and therapeutic modalities are diverse, ranging from small molecules, to peptides, to antibodies, now bispecific, other recombinant proteins to antibody- drug-conjugates (ADCs), to oligonucleotides like RNA, viral vector and cell and gene therapy. In what ways has ten23 health been a pioneer in introducing innovative solutions to the pharmaceutical landscape? We provide innovative solutions with our services: we can develop and manufacture highly complex formulations and sterile dosage forms, e.g. for subcutaneous use or intravitreal use. Such sterile medicines can provide a variety of challenges, related stability, manufacturability, usability as well as sustainability. Our team can anticipate these challenges, provide options and recommendations and drive mitigations. Our perspective is long-term, also with some our innovation programs – for example, we explore the use of AI for sustainable process designs in collaboration with an external partner or participate at the innovation and research of materials that can be used for pharmaceutical production, yet is not plastic based and single-use. Most of these medicines are sterile dosage forms (parenteral preparations), i.e. need to be injected or infused. ten23 can support the development of all these dosage forms. What will be your advice for emerging leaders aspiring to make a positive impact in the healthcare sector? Ask ‘why’ many times. Challenge the status quo. Keep a learning and growth mindset. How do you stay updated on the latest trends and advancements in the pharmaceutical industry? Our team and experts are strongly networked and connected with several experts in the field, both in industry and academy. We also believe that our team in some areas has and can contribute to the advancement of pharmaceutical industry, by pushing the boundaries of traditional beliefs. How do you ensure that patient-centricity remains a core focus in the company's endeavors? The key question for any customer project is whether there 24 | February 2024 www.eurohealthleaders.com

Catalysts for Change Healthcare Leadship Strategies in Europe T innovation to improve access, quality and sustainability. But transforming complex systems isn't easy. It requires vision, collaboration, and the courage to challenge the status quo. he healthcare landscape in Europe is changing rapidly. From digital health solutions to new care models, leaders across the continent are driving Patient-Centred Models European healthcare systems aim to provide comprehensive, integrated care centred around patients' needs. Multidisciplinary teams work together across care settings to coordinate treatment. Patients have more choice and control over their care options. Accountable care organisations that receive bundled payments for patients' total care are responsible for quality outcomes. This transition to value-based care is improving population health at a lower cost. In this article, we'll explore some of the most exciting healthcare leadership strategies emerging from Europe. The State of Healthcare in Europe Universal Coverage Leadership Strategies Most European countries provide universal healthcare coverage to citizens, regardless of ability to pay. While there are some private options, the majority of Europeans receive high-quality care through government-funded insurance plans. With healthcare viewed as a basic human right, European systems aim for equity of access. Costs are controlled through measures like price setting for drugs and medical services. European healthcare leaders are pioneering innovative strategies to improve care. They are focusing on preventative care, adopting digital health solutions and building integrated care models. Countries like the Netherlands, Denmark and Sweden spend a large portion of their healthcare budget on public health and prevention. This proactive approach is paying off with citizens living longer, healthier lives. Key Challenges Facing European Healthcare Systems Technology & Data Ageing Populations Many European countries are leading the way with digital health. Electronic health records are widespread, allowing patient data to be securely shared between providers. Artificial intelligence and big data analytics are being used to gain insights, improve diagnoses and make more accurate treatment plans. Wearable tech and mobile apps are being prescribed to help patients better manage conditions at home. Europe has some of the oldest populations in the world. An ageing population means greater demand for healthcare services and higher costs. European healthcare leaders need innovative strategies to provide high-quality, affordable care for more seniors. Some countries are improving home care and community care options so people can stay in their homes longer. Others are leveraging technology like telehealth to make care more accessible. 26 | February 2024 www.eurohealthleaders.com 27 | February 2024 www.eurohealthleaders.com

Rising Healthcare Costs Public-Private Partnerships Healthcare costs have been rising faster than economic growth in most European countries. New medical technologies, expensive prescription drugs, and increased demand from ageing populations all contribute to higher costs. To curb spending, countries have implemented measures like centralizing purchasing to get lower prices, cutting reimbursements for ineffective treatments, and shifting more costs to consumers. Leaders are also looking at value- based healthcare models that focus on outcomes rather than volume of services. European healthcare leaders are establishing partnerships across public, private and non-profit sectors to drive innovation. Collaboration allows for knowledge sharing, cost savings, and improved quality of care. An example is a partnership between the UK's National Health Service and private companies to develop new treatments for cancer and rare diseases. Cross-sector partnerships are a catalyst for developing new models of integrated care focused on patients. Value-Based Healthcare Stay in touch. Inequalities in Access There is a shift towards value-based healthcare, where providers are paid based on patient outcomes rather than services performed. Healthcare leaders are developing new payment models that reward good outcomes and patient experience. For example, Germany has been a leader in bundled payments where providers receive a single payment to manage a patient's condition or treatment across a whole episode of care. Value-based models are paving the way for affordable, high-quality care focused on population health. Subscribe to Euro Health Leaders and get the magazine in print, & digital on www.eurohealthleaders.com There are substantial disparities in healthcare access across European countries and within populations. Not all citizens have access to the latest treatments and technologies. Rural and low- income populations often face more barriers. Countries are working to provide universal healthcare coverage and minimize regional disparities. Some are also targeting health inequalities through public health initiatives around prevention and health literacy. Innovative Strategies of Healthcare Leaders Conclusion Embracing Digital Technologies Healthcare leaders across Europe are innovating and driving positive change. By embracing technology, focusing on preventative care, and putting the patient experience first, they're transforming systems and improving outcomes. We can all learn something from their bold visions and willingness to challenge the status quo! European healthcare leaders are at the forefront of utilizing advanced digital technologies to improve patient care. Electronic health records, telemedicine, and health apps are being adopted to increase efficiency, expand access, and enable preventive care. For example, Estonia has made digital health a priority and 99% of health data is digitized. Patients can access records and book appointments online, and doctors can prescribe medication electronically. Focus on Prevention and Wellness Email: info@eurohealthleaders.com For Subscription: www.eurohealthleaders.com - Natalie May Rather than just treating illness, European healthcare leaders are focusing on prevention and wellness. They are promoting healthy lifestyles, increasing health education, and making preventive care more accessible. For instance, the Finnish government's health program aims to curb lifestyle diseases through exercise, nutrition, and limiting alcohol and tobacco use. Free preventive care and health check-ups are offered. 28 | February 2024 www.eurohealthleaders.com

L E A D E R S EUR Health www.eurohealthleaders.com

Europe's Pioneering Leaders Shaping the Future of Healthcare- Edition 2

Europe's Pioneering Leaders Shaping the Future of Healthcare- Edition 2

Presentation Transcript

Shaping the Future of Transition

Shaping the Future:

The role of Universities in shaping the future of Europe

Shaping the future of soroptimist

LEADERS OF THE FUTURE

Shaping the Future

Shaping the Future

Shaping the future

Shaping the Future

Shaping the future of Waterbeach

The role of Universities in shaping the future of Europe

Shaping the Future of Transition

How Wearables Are Shaping The Future Of Healthcare?

IILM Shaping Future Business Leaders

Indian Tutors Shaping Future Leaders

Top 5 Pioneering Healthcare Leaders in 2023

UIHM_ Shaping Future Hospitality Leaders in the City of Lakes

Pioneering Technologist Shaping the Future with Innovation and Inclusion

World’s Most Pioneering Leaders in Healthcare, 2023

Solan Pharma: Shaping the Future of Healthcare

Remote Patient Monitoring_ Shaping the Future of Healthcare

Pioneering Leaders Shaping the Future of Healthcare, 2024